A Novel Cerebral Spinal Fluid (CSF) Assay for Assessing HER2 Genetic Heterogeneity and Monitoring Treatment Response in Patients with Leptomeningeal Metastases (LM)
Time: 2:30 pm
day: Day One
Details:
-
- CNSide is a novel cerebral spinal fluid (CSF)-based assay that uses a combination of cell-based and cell-free DNA (cfDNA) analysis to evaluate patients with CNS metastasis
- Aids physicians in following:
- Identification of tumor cells in CSF
- Characterization of tumor heterogeneity in biomarker targets
- Monitoring of therapy response with serial quantitative tumor cell counts
- Can be used to identify HER2 amplification and other actionable biomarkers in patients with breast cancer and suspected or diagnosed LMD
